Hearing Your Story
The only thing more powerful than a story, is a decision. Help men find their way through prostate cancer treatment choices by telling your story here on Twice As Many.
Phase III Trial Comparing Orteronel (TAK-700) Plus Prednisone Against Placebo Plus Prednisone Fails
Reporting both negative clinical trial results is as important as reporting positive results. However, pharmaceutical companies often bury negative results. Fortunately (actually unfortunately because there were negative results) a Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed [...]
Lethal Advanced Prostate Cancer Has Inherently Heterogeneity And Can Spread From Other Metastatic Sites
We still have a lot to learn about how prostate cancer actually spreads, or metastasizes. Current theory holds that the primary tumor is probably most responsible for the development of distant metastases. In a new genomic analysis of tissue performed at the Johns Hopkins University using tissue from prostate cancer patients this paradigm has been [...]
Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer *
Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not [...]
Using CT Scans to Predict A Pending Spinal Cord Compression in Men With Castration-Resistant Prostate Cancer *
CT scans are often performed in the process of monitoring of advanced prostate cancer disease progression. One of the most serious impacts of advanced prostate cancer is spinal compression, which can lead to paralysis and significant pain. Being able to use the CT scan as a red flag warning about potential spinal cord compression could [...]
Detecting Prostate Cancer Cells in Blood Can Give An Early Warning of Treatment Failure and Shorten Clinical Trials
There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is working or not working. A major new study showed that the number of these circulating tumor cells in the blood [...]
A Real Role for Immunotherapy in the Treatment of Advanced Prostate Cancer
Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy by critics. The common criticism leveled at Provenge can be summed up simply, “It doesn’t work.” The plain truth is [...]
AdVance Transobturator Male Sling for Post-Prostatectomy Incontinence – A Retrospective Study of Its Efficacy *
One of the more difficult problems faced by some men treated with surgery as their primary treatment modality is post-prostatectomy incontinence (PPI). PPI can affect the quality of life for both men successfully treated as well as those who go on and eventually develop advanced prostate cancer. One of the more common, but last efforts [...]
Coming Back to Continue the Blog and New Data Disclosed on Enzalutamide at the Plenary Session at the 2015 European Association of Urology Congress
Before I get into the meat of today’s post about enzalutamide, I want to briefly make some personal comments about my absence from this blog. As I had mentioned I have been diagnosed with a fifth primary cancer, appendiceal cancer. It is a rare cancer, which required my having to remove my appendix, a piece [...]
The Twists and Turns For Provenge
It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are [...]